Düsseldorf
09.10.26 | 19:30
5,260 Euro
+8,57 % +0,415
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,210 | 5,430 | 09.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | Needham raises Shattuck Labs stock price target on HS trial plans | 2 | Investing.com | ||
| 01.10. | Shattuck Labs plans phase 2 trial for SL-325 in hidradenitis suppurativa | 1 | Investing.com | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 01.10. | Shattuck Labs, Inc.: Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development | 457 | GlobeNewswire (Europe) | - RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first... ► Artikel lesen | |
| 08.09. | Shattuck Labs auf Wells Fargo Konferenz: Strategie fokussiert sich auf DR3-Blockade | 2 | Investing.com Deutsch | ||
| 25.08. | What Shattuck Labs Stock Topped the Market on Monday | 3 | The Motley Fool | ||
| 12.08. | H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion | 1 | Investing.com | ||
| 12.08. | H.C. Wainwright senkt Kursziel für Shattuck Labs wegen Studienerweiterung | 3 | Investing.com Deutsch | ||
| 11.08. | Shattuck Labs, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | Shattuck Labs Aktie gibt nach Quartalsbericht nach | 6 | Investing.com Deutsch | ||
| 11.08. | Shattuck Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Shattuck Labs GAAP EPS of -$0.12 in-line | 3 | Seeking Alpha | ||
| 11.08. | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | 559 | GlobeNewswire (Europe) | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| 25.07. | Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday | 1 | The Motley Fool | ||
| 24.07. | This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday | 1 | Benzinga.com | ||
| 24.07. | JPMorgan reiterates Shattuck Labs stock rating on DR3 program | 4 | Investing.com | ||
| 11.06. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Shattuck Labs drops 6%, prices $75M share raise at $4 per share | 1 | Seeking Alpha | ||
| 10.06. | Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr | 341 | AFX News | WASHINGTON (dpa-AFX) - Shattuck Labs, Inc. (STTK), a clinical-stage biotechnology company, on Wednesday revealed the pricing of its earlier announced public offering of 10.88 million shares... ► Artikel lesen | |
| 10.06. | Shattuck Labs prices $75M public offering at $4 per share | 1 | Investing.com |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,548 | -0,89 % | Valneva: Großbritannien entzieht Chikungunya-Impfstoff die Zulassung | Valneva verliert in Großbritannien die Marktzulassung für seinen Chikungunya-Impfstoff IXCHIQ. Die britische Arzneimittelbehörde MHRA hat die Genehmigung nach einer erneuten Nutzen-Risiko-Bewertung... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 8,510 | -1,05 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,851 | -0,23 % | Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate | European Affiliate, based in Amsterdam, to support upcoming marketing authorization submissions, OCU410 Phase 3 development program, and potential commercialization in Europe MALVERN, Pa., Oct. 06... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,040 | +0,48 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,363 | -5,47 % | 7 Jahre USA, 10 Jahre EU: Warum Biogen, Novartis und NurExone auf den Orphan-Drug-Pfad setzen | ||
| SAREPTA THERAPEUTICS | 15,920 | -0,13 % | Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,151 | +3,61 % | Pacific Biosciences Collaborates With TychoBio For AI-powered RNA Data Creation; Shares Up | ||
| REDHILL BIOPHARMA | 0,539 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,196 | -2,14 % | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,800 | +0,74 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERASTEM | 7,144 | -4,70 % | Verastem stock maintained at Buy by BTIG ahead of data readout | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,462 | 0,00 % | Volta Labs launches automated library preparation solution for the Oxford Nanopore Ligation Sequencing Kit V14 | BOSTON, May 21, 2026 /PRNewswire/ -- Volta Labs, maker of the Callisto Sample Prep System, today announced the availability of its DNA Library Preparation Application for the Oxford Nanopore... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,174 | 0,00 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,330 | +1,75 % | Rocket Pharma upgraded at Goldman Sachs on Danon disease therapy | ||
| PALISADE BIO | 1,535 | -0,32 % | Raymond James nimmt Coverage für Palisade Bio mit "Outperform" auf |
SHATTUCK LABS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +8,57 % bei einem Aktienkurs von 5,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.